Found Tirzepatide Review (2026): Real Price at Every Dose

Price at every dose tier

This is the table that matters. The advertised figure applies to the starter dose you will occupy for roughly four weeks; the row you should budget from is 10 mg.

We do not currently publish an outbound link for this program. Search for it directly rather than following an advertisement.

Pricing source: GLP-1 Watchdog provider index (secondary source). Last verified 2026-08-05.

What works

• Behavioural and coaching infrastructure alongside medication
• Established brand with a large member base

What to check before enrolling

• Membership stacks on top of the medication price
• Total monthly cost lands near the top of the market
• Pharmacy partner not disclosed

Clinical and pharmacy disclosure

If Found is not the right fit

The cheapest tracked flat-rate program is IVIM Health at $133 per month. For FDA-approved product rather than compounded, LillyDirect self-pay Zepbound vials run $299–$449 depending on strength — see the Zepbound cost breakdown.

Found tirzepatide price as your dose climbs

Found charges $398 at 2.5 mg and $398 at 10 mg — the same number. Escalating does not reprice you, which means the figure you are quoted in week one is the figure you are still paying in month ten. That is the whole argument for flat pricing, and it is worth more than most entry discounts.

Is Found tirzepatide cheap compared with the market?

On our twelve-month model this program ranks 19 of 23 tracked routes at about $4,776. The cheapest tracked route, Oak Longevity, comes in about $2,388 lower over the same year. Whether that gap is worth paying depends on what this program provides that the cheaper one does not — which is a question about disclosure, support and reliability rather than about the molecule, since the molecule is identical.

Seven questions to ask Found before you enrol

1. What will I pay in total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, and what is its state license?
3. Is the prescribing clinician licensed in my state, and can I have their name?
4. What is the vial concentration, and what is the beyond-use date?
5. Does the quoted rate hold at renewal, or does it revert?
6. What happens if a shipment arrives warm — who pays for the replacement?
7. What notice do I need to give to cancel before the next cycle?

None of these requires clinical training to evaluate, and all of them are answerable in writing. A program that will not answer the pharmacy question has told you what you needed to know. Our verification walkthrough covers how to check the answers against public records.

Found tirzepatide cost by maintenance dose and duration

One annual figure assumes one maintenance dose. Nobody knows theirs at intake, so here is what Found costs across every plausible outcome, over one, two and three years.

Because Found holds one price at every strength, the rows above differ only in the small titration effect, not in the maintenance rate. Whether you settle at 5 mg or run to the 15 mg ceiling, a year costs about $4,776 and three years about $12,736. That predictability is the reason to choose a flat programme even when a dose-scaled competitor advertises lower: you are buying a budget you can hold rather than a number that moves under you.

The corollary is that flat pricing is worst value at the starter dose and best value at the ceiling. In month one you are paying a maintenance rate for an initiation dose. If you know in advance that you will hold at 5 mg permanently, a dose-scaled programme may well beat this one — check the per-tier table above rather than assuming flat always wins.

Found against the programs priced closest to it

Comparing against the whole market is noise; comparing against the three routes nearest your price point is a decision. These are the programs you are realistically choosing between.

Pausing or restarting Found

Pausing is more expensive than it looks, and the cost is clinical before it is financial. Stop for a month and appetite returns before the metabolic adaptation to a lower weight does; stop for several and tolerance fades, which means most prescribers restart you low and re-titrate. On Found's pricing that re-titration costs you two months back at $398 and $398 respectively, which is the same as your maintenance rate here, so the financial penalty is zero and the penalty is purely in lost time and regained weight.

If cost is the reason you are considering a pause, price the market before you stop rather than after. The cheapest tracked route, Oak Longevity, runs about $2,388 for a year against $4,776 here. Switching programs is almost always better than interrupting therapy, because the interruption is the thing that undoes the result.

What Found publishes, and what it does not

Found scores 75/100 on our published criteria. It publishes: price published at all six dose tiers; price does not rise as the dose escalates; prepaid term and its rate published; state availability published; delivery formats published. It does not publish: dispensing pharmacy or prescriber identified by name; no separate recurring membership fee. For context the highest-scoring tracked route is Yucca Health at 100/100.

None of that measures whether the care is good. A program can publish everything and ship late; another can publish nothing and employ excellent clinicians. What disclosure measures is how much you can verify before you hand over money and a medical history — and in a market where the FDA has taken enforcement action against telehealth marketing, being able to verify things beforehand is not a small property.

Found availability, formats and shipping

Found publishes availability in 50 states. Availability is governed by two licences lining up — the prescriber must hold one in your state and the pharmacy must be registered to ship into it — so gaps in a service map are regulatory rather than commercial. Confirm at checkout rather than relying on any published list, including ours; see tirzepatide by state for what applies where you live.

Delivery formats here: injection. A single format keeps dosing simple: one concentration, one syringe, one instruction set. If injection anxiety is your obstacle, programs offering sublingual or tablet formats exist, with the caveat that published bioavailability evidence for those preparations is limited.

Found against the pre-payment checklist

Six checks, all answerable before you pay, none requiring clinical training.

A program failing one of these is not disqualified — a dose-scaled price is a commercial choice, not misconduct. A program that will not answer the pharmacy question is a different matter, because it is asking you to inject weekly something it will not identify. Our verification walkthrough covers how to check the answers against state board records and FDA registrations, both of which are free and take minutes.

What Found includes, and what it bills separately

Found splits the charge: medication plus $99 a month for the platform. Whether that earns its cost depends entirely on whether you use it. Unlimited clinician messaging is genuinely valuable during titration, when dose questions arrive weekly, and close to idle at stable maintenance. Ask what happens to your prescription if the membership lapses mid-supply — if the medication stops, that is a business model imposing itself on a clinical relationship.

Found commitment terms in practice

No discounted prepaid term is published, which means Found is not asking you to put money at risk before you know whether you tolerate the drug — and is not offering a lower rate for accepting that risk either. For a first three months that is the safer structure; for a stable long-term patient it leaves a discount on the table that some competitors offer.

Who should not choose Found

Anyone who expects to hold a low maintenance dose permanently, because flat pricing is worst value at the bottom of the ladder — you would be paying a maintenance rate for a starter dose. Anyone who needs an FDA-approved product, since this is a compounded preparation that FDA does not review for safety, effectiveness or quality before marketing. And anyone who cannot get a straight answer to the pharmacy question, whatever the price.

How Found fits the wider market

Entry pricing across the 21 tracked compounded programs runs $133 to $399 a month for the identical molecule from the same category of licensed pharmacy, and the cheapest route holds a 10 mg maintenance dose at $199. Found sits at $398 at that dose. Nothing about the medicine differs across that spread; what differs is overhead, clinical wrap, pharmacy sourcing and margin. Use the projector to price your own maintenance dose across all of them rather than accepting any single program's framing, including this page's.

What would change our record of Found

Four things. A published price we can verify at a dose tier currently blank. A named dispensing pharmacy with a checkable state licence. A change to the pricing model, in either direction. Or a correction from a reader or from the program itself with a source we can check. All four are logged with the date they changed, and the underlying record is in the open dataset rather than locked inside a page.

We do not accept payment to change any of it, and no program has editorial input into what appears here. Where a program disputes a figure, the fastest route is to publish the correct one publicly — at which point we record it, date it and move on.

Found and the compounded-versus-brand decision

This is a compounded route. FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before marketing, which is the honest reason it costs a fraction of the brand price. What you retain is a licensed pharmacy under a state board, a prescriber who can decline, and at good operations batch sterility and potency testing you can ask about.

Neither choice is obviously right. What is wrong is making it without knowing which one you are buying, and the marketing in this market frequently blurs exactly that line — which is why every page here states the regulatory status plainly rather than in a footer.

Using Found well if you do enrol

Fix a weekly injection day and keep it. Record the dose, the date and the injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if there is an introductory rate. And re-price the market annually at your actual maintenance dose — no program tells its existing patients when a competitor drops below it, and the cheapest tracked route currently holds maintenance at $199 a month, about $2,388 for a year.

Found tirzepatide: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

Found tirzepatide: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

Found tirzepatide: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.